Method for treatment of hypertension
Inventors
Snyder, Eric • Sprissler, Ryan • Bowman, Benjamin • Snyder, Scott C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12351873-B2
Publication Date
2025-07-08
Expiration Date
Abstract
The present invention concerns selective renal denervation treatment of drug resistant hypertensive patients by correlating the patients' genetic panel by categorization and hierarchy according to patients' genetic variants within the functional genes for heart activity, for the renin-angiotensin aldosterone system, and for renal activity.
Core Innovation
The invention relates to a method for renal denervation treatment of a human patient with cardiovascular hypertension. The method involves obtaining a nucleic acid sample from the patient comprising gene sequences of ADRA2A, ADRA2C, ADRB1, ADRB2, renin, AGT, ACE, AGT1R, WNK1, ADD1, SLC12A3 and SCNN1A genes. The nucleic acid sample is screened to determine whether the sample contains one or more of gene sequences of categories A, B, C, D and E to thereby obtain a genetic panel.
The genetic panel is used to classify the patient according to protocols, where Protocol 1i includes all gene sequences of categories A, B, C, D and E; Protocol 1ii includes all gene sequences of categories A, B, C and D but no gene sequence of category E; Protocol 2 includes all gene sequences of categories A, B and D, the gene sequences C1 and C2 of category C, and all gene sequences of category D; and Protocol 3 includes all gene sequences of categories A, B and D. Based on the classification, responsiveness is graded in a predicted manner using hierarchical genetic categories across categories A–E.
After classification, the method conducts at least a partial surgical denervation of the sympathetic nerves lining the nephritic arteries of one or both of the patient’s kidneys to produce a treated patient. The treatment is performed when the patient is classified as having Protocol 1i, 1ii, 2 or 3. Separate protocol concepts are also described as treatment concepts in which the denervation is selected using the patient’s genetic panel category profile.
Claims Coverage
The partial content includes two independent claims: clm-00001 and clm-00010. The inventive features center on genetic panel screening for categories A–E and protocol- or procedure-based selection of surgical renal denervation.
Genetic panel screening and protocol-based classification for treatment
A method for renal denervation treatment of a human patient with cardiovascular hypertension comprising obtaining a nucleic acid sample comprising gene sequences of ADRA2A, ADRA2C, ADRB1, ADRB2, renin, AGT, ACE, AGT1R, WNK1, ADD1, SLC12A3 and SCNN1A genes; screening the nucleic acid sample to determine whether the sample contains one or more of gene sequences of categories A, B, C, D and E to thereby obtain a genetic panel; classifying the patient according to protocols Protocol 1i, Protocol 1ii, Protocol 2 or Protocol 3 based on which category gene sequences are present; and conducting at least a partial surgical denervation of the sympathetic nerves lining the nephritic arteries of one or both of the patient’s kidneys when the patient is classified as having Protocol 1i, 1ii, 2 or 3.
Procedure-based distal/proximal nephritic denervation selected by category-defined nucleic acid sequences
A method for treatment of a human patient with cardiovascular hypertension comprising conducting a treatment of at least a partial surgical denervation of one to twelve treatments of the sympathetic nerves lining one or both nephritic arteries at the arterial distal region relative to the patient’s kidney or kidneys when the patient has been determined to have all nucleic acid sequences of categories A, B, C, D and E; conducting a treatment of surgical denervation of one to eight treatments of the sympathetic nerves lining one or both nephritic arteries at the arterial proximal region relative to the patient’s kidney or kidneys when the patient has been determined to have all nucleic acid sequences of categories A, B, C, D but not any sequences of category E; conducting a treatment of surgical denervation of six to twelve treatments of the sympathetic nerves lining one or both nephritic arteries at the arterial proximal region relative to the patient’s kidney or kidneys when the patient has been determined to have all nucleic acid sequences of categories A, B, D and sequences C1 and C2 of category C but not any of category C3 or C4 of category C or category E; or the patient has been determined to have all nucleic acid sequences of categories A, B and D but not any of category C or E; wherein the nucleic acid sequences of categories A, B, C, D and E are defined by specific ADRA2A, ADRA2C, ADRB1, ADRB2, renin, AGT, ACE, AGT1R, WNK1, ADD1, SLC12A3 and SCNN1A nucleic acid variants.
Across the independent claims, the inventive focus is the use of a genetic panel screening for specific nucleic acid gene sequences categorized as A–E, followed by protocol- or procedure-based patient grouping that selects whether and where surgical denervation of sympathetic nerves lining nephritic arteries is performed.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?